A platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical care, 2026, Fatemeh Keyvani et al

Mij

Senior Member (Voting Rights)
Editor's summary:
Cerebrospinal fluid (CSF) biomarkers are important for monitoring pathophysiological changes in neurocritical care. However, slow turnaround times of traditional laboratory analysis hinder fast decision-making based on these markers. Here, Keyvani et al. developed a platform for near real-time monitoring of CSF flow, pH, glucose, and lactate levels. The platform consists of four integrated sensors that are connected to standard external ventricular drain tubing and an electrochemical analyzer. Benchtop simulations confirmed selectivity, stability, and sensitivity of the device, and measurements in patients correlated with clinical reference assays, highlighting the potential of this platform for neurocritical care.

Abstract
Real-time monitoring of cerebrospinal fluid (CSF) is critical in intensive care units for the timely management of complications such as infection and mechanical malfunction in patients with external ventricular drainage systems.

Current practice relies on intermittent CSF sampling for laboratory-based biomarker analysis and manual inspection, resulting in delayed reporting and intervention. To address these limitations, we developed NeuroSense, a multiplexed sensing platform that integrates with standard external ventricular drainage systems to enable near real-time monitoring of key CSF (bio)markers, including glucose, lactate, pH, and flow rate, that are essential for detecting infection and drain dysfunction.

NeuroSense incorporates glucose and lactate aptamer–based electrochemical biosensors, a polydopamine pH sensor, and an impedance-based flow sensor. Validation in simulated conditions demonstrated sensor specificity, stability in human CSF for several days, and ethylene-oxide sterilization compatibility.

Evaluation in patients hospitalized in intensive care unit demonstrated strong correlation with clinical reference standards. By providing near real-time bedside assessment, NeuroSense has the potential to improve temporal resolution for detection of biomarker trends and drain malfunction indicators.
LINK
 
Not useful for studying ME as it is, but with the "divert some of the fluid into sensors" technology validated, it's easy enough to add more sophisticated sensors. I don't know whether ME (or PEM) has a marker in the CSF, but I also don't know that it doesn't have one.
 
Back
Top Bottom